Barinthus Biotherapeutics plc. 8-K

What Happened

• On April 30, 2026, Barinthus Biotherapeutics plc (BRNS) announced and furnished a press release reporting the company’s financial results and an overview of business progress for the quarter ended March 31, 2026. The press release is included as Exhibit 99.1 to the Form 8-K. The filing was signed by CEO William Enright.

Key Details

• Filing date: April 30, 2026 (Form 8‑K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: quarter ended March 31, 2026 (Q1 2026).
• Disclosure provided via press release (Exhibit 99.1); interactive XBRL cover page also furnished (exhibit 104).
• Report signed and submitted by Chief Executive Officer William Enright.

Why It Matters

• This filing notifies investors that Barinthus has released its latest quarterly earnings and operational update; investors should review the Exhibit 99.1 press release for the company’s reported revenue, expenses, cash position, and any clinical or corporate updates. The 8‑K itself confirms the timing and official nature of the disclosure but does not include the numeric details in-line—those are in the attached press release.